DERMJourney Medical Corp
$6.22
$0.30
(5.07%)
Closed $6.22
$0.00
(0.00%)
After Hours
EarningsAug 11
Mkt Cap$171.26M
Vol410,348.00
Fundamentals
Here's What Key Metrics Tell Us About Journey Medical (DERM) Q1 Earnings
The headline numbers for Journey Medical (DERM) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Zacks
Journey Medical Corporation (DERM) Reports Q1 Loss, Beats Revenue Estimates
Journey Medical (DERM) delivered earnings and revenue surprises of -14.29% and +5.84%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Aurinia Pharmaceuticals (AUPH) Q1 Earnings and Revenues Top Estimates
Aurinia (AUPH) delivered earnings and revenue surprises of +38.89% and +0.39%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Zevra Therapeutics (ZVRA) Q1 Earnings and Revenues Surpass Estimates
Zevra Therapeutics (ZVRA) delivered earnings and revenue surprises of +184.36% and +15.51%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Will Journey Medical Corporation (DERM) Report Negative Q1 Earnings? What You Should Know
Journey Medical (DERM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks
Assertio (ASRT) Moves 17.0% Higher: Will This Strength Last?
Assertio (ASRT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Zacks
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Journey Medical Corporation - DERM
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Journey Medical Corporation - DERM INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of...
PR Newswire
Q1 EPS Estimates for Journey Medical Cut by HC Wainwright
Journey Medical Corporation (NASDAQ:DERM - Free Report) - Equities research analysts at HC Wainwright lowered their Q1 2026 earnings estimates for Journey Medical in a report issued on Thursday...
MarketBeat
Journey Medical Corporation (NASDAQ:DERM) Receives Average Rating of "Hold" from Analysts
Shares of Journey Medical Corporation (NASDAQ:DERM - Get Free Report) have received a consensus rating of "Hold" from the five brokerages that are covering the company, Marketbeat.com reports. One...
MarketBeat
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Journey Medical Corporation - DERM
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Journey Medical Corporation - DERM INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Journey Medical Corporation - DERM PR Newswire NEW YORK, April 16, 2026 NEW YORK, April 16, 2026...
PR Newswire
<
1
2
...
>